natgillin/translations-raw huggingface dataset:
The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies. 
Doza od 1800 mg/kg/dan izazvala je znatnu maternalnu toksičnost i smanjenje fetalne težine, povezane s povećanom pojavnošću fetusa s anomalijama srčano-žilnog sustava i kostura.
Actavis treatment for as long as your doctor has told you. 
Levetiracetam Actavis onoliko dugo koliko je liječnik odredio.
• Levetiracetam Actavis is used as a chronic treatment. 
• Levetiracetam Actavis se koristi za dugotrajno liječenje.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants >1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. 
Nuspojave zabilježene tijekom kliničkih ispitivanja (odrasli, adolescenti, djeca i dojenčad starija od 1 mjeseca) ili iskustva nakon stavljanja lijeka u promet navedene su u sljedećoj tablici s obzirom na organski sustav i učestalost.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type 
Studije in vitro pokazuju da levetiracetam utječe na razinu Ca2+ u neuronima na način da djelomično inhibira
Perforated unit dose blisters: 60 x 1 film-coated tablets. 
Perforirani blisteri djeljivi na jedinične doze: 60 x 1 filmom obloženih tableta.
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline. 
No u ispitanika koji su uzimali levetiracetam tijekom dugoročnog, otvorenog ispitivanja provedenog praćenjem u prosjeku nije bilo pogoršanja bihevioralnog i emocionalnog funkcioniranja, a osobito nije bilo pogoršanja pokazatelja agresivnog ponašanja u odnosu na početno stanje.
The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. 
Profil nuspojave levetiracetama općenito je sličan u svim starosnim skupinama i u svim odobrenim indikacijama epilepsije.
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis). 
• osip kože koji se može formirati u mjehuriće i izgledati kao male mete (sa središnjim tamnim točkama okruženim bljeđim područjem i tamnim prstenom oko ruba) (erythema multiforme), jako rasprostranjen osip s mjehurićima i kožom koja se ljušti, osobito oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom), i mnogo teži oblik koji uzrokuje ljuštenje kože na više od 30% površine tijela (toksična epidermalna nekroliza).
58.3 % of the levetiracetam treated patients and 23.3 % of the patients on placebo had at least a 50 % reduction in myoclonic seizure days per week. 
58,3% bolesnika liječenih levetiracetamom i 23,3% bolesnika koji su dobivali placebo imalo je barem 50%-tno smanjenje broja dana s miokloničkim napadajima tjedno.
500 to 1,500 mg twice daily 500 to 1,000 mg twice daily 250 to 750 mg twice daily 
500 do 1500 mg dva puta na dan 500 do 1000 mg dva puta na dan 250 do 750 mg dva puta na dan
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6]) and epoxide hydroxylase activities. 
In vitro je pokazano da levetiracetam i njegov glavni metabolit ne inhibiraju aktivnost izoformi glavnog humanog citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 i 1A2), glukuronil transferaze
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks). 
(primjerice, kod odraslih i adolescenata koji su teži više od 50 kg: smanjenja doze od 500 mg dva puta na dan svaka dva do četiri tjedna; u dojenčadi starije od 6 mjeseci, djece i adolescenata koji teže manje od 50 kg: smanjenje doze ne smije premašiti 10 mg/kg dva puta na dan svaka dva tjedna; u dojenčadi (mlađe od 6 mjeseci): smanjenje doze ne smije premašiti 7 mg/kg dva puta na dan svaka dva tjedna).
Tjoapack Netherlands B.V. Nieuwe Donk 9, ETTEN-LEUR, 4879AC, Netherlands 
Nieuwe Donk 9, ETTEN-LEUR, 4879AC, Nizozemska
In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6 % for patients on placebo. 
Analizom zbirnih podataka utvrđeno je da je postotak bolesnika kod kojih je postignuto 50%-tno ili više smanjenje od početne učestalosti djelomičnih napadaja tjedno uz konstantnu dozu (12/14 tjedana) bio 27,7% kod uzetih 1000 mg, 31,6% kod uzetih 2000 mg i 41,3% kod uzetih 3000 mg levetiracetama te 12,6% kod uzimanja placeba.
Each film-coated tablet contains 0.156 mg sunset yellow E110. 
Jedna filmom obložena tableta sadrži 0,156 mg boje sunset yellow E110.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. 
Na početku liječenja ili povećanja doze nuspojave, nuspojave poput pospanosti, umora i omaglice, mogu se češće javiti.
A. Potamitis Medicare Ltd Τηλ: +357 22583333 
Potamitis Medicare Ltd Τηλ: +357 22583333
Levetiracetam Actavis 750 mg contains colouring agent sunset yellow (E110) which may cause allergic reactions. 
Levetiracetam Actavis 750 mg sadrži boju sunset yellow (E110) koja može uzrokovati alergijske reakcije.
Add-on therapy for adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more The initial therapeutic dose is 500 mg twice daily. 
Dodatna terapija za odrasle (≥18 godina) i adolescente (12 do 17 godina) teške 50 kg ili više Početna terapijska doza iznosi 500 mg dva puta na dan.
Sunset Yellow (E110) colouring agent may cause allergic reactions. 
Bojilo sunset yellow FCF (E110) može izazvati alergijske reakcije.
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula): 
Klirens kreatinina u ml/min/1,73 m2 može se za mlade adolescente, djecu i dojenčad procijeniti iz vrijednosti serumskoga kreatinina (mg/dl) s pomoću sljedeće formule (Schwartzova formula):
What you need to know before you take Levetiracetam Actavis Do not take Levetiracetam Actavis 
Što morate znati prije nego počnete uzimati Levetiracetam Actavis
The mechanism of action of levetiracetam still remains to be fully elucidated. 
Mehanizam djelovanja Mehanizam djelovanja levetiracetama nije u potpunosti razriješen.
Peak concentrations (Cmax) are typically 31 and 43 μg/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively. 
Vršna koncentracija (Cmax) uglavnom je 31 μg/ml nakon jedne doze od 1000 mg i 43 μg/ml nakon ponovljene doze od 1000 mg dva puta na dan.
CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73 BSA subject (m2) 
CLcr (ml/min/1,73 m2) = ---------------------------- x 1,73 PT bolesnika (m2)
For children 6 years and above, an oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. 
Za djecu od 6 godina i stariju, oralnu otopinu treba koristiti za doze ispod 250 mg, za doze koje nisu višestruke doze od 250 mg kada se preporuka za doziranje ne može postići uzimanjem više tableta i za bolesnike koji ne mogu gutati tablete.
You should not drive or use machines until it is established that your ability to perform such activities is not affected. 
Ne smijete voziti ili se koristiti strojevima dok se ne utvrdi da uzimanje lijeka Levetiracetam Actavis ne utječe na Vaše sposobnosti za to.
Specifar S.A 1, 28 Octovriou str. 123 51 Ag. Varvara Athens 
1, 28 Octovriou str., 123 51 Ag.
The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session. 
Frakcijsko uklanjanje levetiracetama iznosi 51% tijekom uobičajene četverosatne dijalize.
More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5 % of subjects on levetiracetam and on carbamazepine CR respectively). 
Više od pola ispitanika 12 mjeseci nije imalo napadaje (56,6% bolesnika koji su dobivali levetiracetam i 58,5% ispitanika koji su dobivali karbamazepin s kontroliranim otpuštanjem).
Levetiracetam Actavis is not indicated in children and adolescents below 16 years on its own (monotherapy). 
Levetiracetam Actavis nije indiciran u djece i adolescenata mlađih od 16 godina kao monoterapija.
Tablet containers: 30, 100 and 200 film-coated tablets. 
Spremnici s tabletama: 30, 100 i 200 filmom obloženih tableta.
The risk of anorexia is higher when levetiracetam is coadministered with topiramate. 
Opis izdvojenih nuspojava Rizik anoreksije veći je ako se levetiracetam uzima istodobno s topiramatom.
Creatinine clearance (ml/min/1.73 m2) 
Klirens kreatinina (ml/min/1,73 m2)
• primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). 
primarno generaliziranih toničko-kloničkih napadaja (velikih napadaja, uključujući gubitak svijesti) u odraslih i adolescenata starijih od 12 godina života s idiopatskom generaliziranom epilepsijom (vrsta epilepsije za koju se misli da je genetski uzrokovana).
Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function 
Prilagođavanje doze za odrasle bolesnike i adolescente teške više od 50 kg s oštećenom bubrežnom funkcijom
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. 
Djelotvornost levetiracetama za samostalno liječenje dokazana je kod paralelnih grupa u dvostruko slijepoj usporedbi neinferiornosti s karbamazepinom s kontroliranim otpuštanjem (CR, engl. controlled release) na 576 bolesnika u dobi od 16 godina ili starijih s novo- ili nedavno dijagnosticiranom epilepsijom.
Drug reaction with eosinophilia and systemic symptoms (DRESS), hypersensitivity (including angioedema and anaphylaxis) 
Reakcija na lijek s eozinofilijom i sistemskim simptomima (DRESS), preosjetljivost
Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Levetiracetam Actavis 1,000 mg film-coated tablets 
Levetiracetam Actavis 250 mg filmom obložene tablete Levetiracetam Actavis 500 mg filmom obložene tablete Levetiracetam Actavis 750 mg filmom obložene tablete Levetiracetam Actavis 1000 mg filmom obložene tablete levetiracetam
An oral solution is the preferred formulation for use in infants and children under the age of 6 years. 
Oralna otopina je poželjna formulcija za primjenu u dojenčadi i djece mlađe od 6 godina.
White tablet containers (HDPE) closed with snap-on cap (LDPE) with a tamper evident ring. 
Bijeli spremnici (HDPE) s tabletama zatvoreni zatvaračem (LDPE) i zaštitnim prstenom s evidencijom otvaranja.
• myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; 
miokloničkih napadaja (kratkih, šoku nalik trzanja mišića ili skupine mišića) u odraslih i adolescenata starijih od 12 godina života s juvenilnom miokloničnom epilepsijom;
A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one month to less than six month and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 month to less than 4 years old, was used in this study. 
20 mg/kg/dan titrirana je do 40 mg/kg/dan u dojenčadi u dobi od jednog do manje od 6 mjeseci, a doza od 25 mg/kg/dan titrirana je do 50 mg/kg/dan u dojenčadi i djece u dobi od 6 mjeseci do manje od 4
The tablet formulation is not adapted for use in infants and children under the age of 6 years. 
Farmaceutski oblik tableta nije prilagođena za primjenu u dojenčadi i djece mlađe od 6 godina.
Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more: 
Doza u odraslih i adolescenata (12 do 17 godina) koji imaju 50 kg ili više:
The possible side effects of an overdose of levetiracetam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma. 
Moguće nuspojave predoziranja levetiracetamom su pospanost, uznemirenost, agresija, smanjena pozornost, smetnje disanja i koma.
If you stop taking Levetiracetam Actavis 
Ako prestanete uzimati Levetiracetam Actavis
72.2 % of the levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week. 
U 72,2% bolesnika liječenih levetiracetamom i 45,2% bolesnika koji su dobivali placebo primijećeno je 50%-tno ili više smanjenje učestalosti PGTK napadaja tjedno.
43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders. 
U 44,6% bolesnika liječenih levetiracetamom i 19,6% bolesnika koji su dobivali placebo, zapaženo je
If stopping treatment, Levetiracetam Actavis should be discontinued gradually to avoid an increase of seizures. 
Ako prekidate liječenje lijekom Levetiracetam Actavis prekid mora biti postupan kako bi se izbjeglo pojačanje napadaja.
Renal impairment The daily dose must be individualised according to renal function. 
Dnevna doza određuje se za svakog bolesnika pojedinačno u skladu s bubrežnom funkcijom.
If you forget to take Levetiracetam Actavis 
Ako ste zaboravili uzeti Levetiracetam Actavis
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % 
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: -7,8 8,2).
The most frequently reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. 
Najčešće prijavljene nuspojave su nazofaringitis, somnolencija (pospanost), glavobolja, umor i omaglica.
Dose in infants (1 month to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg: 
Doza u dojenčadi (1 do 23 mjeseca), djece (2 do 11 godina) i adolescenata (12 do 17 godina) koji imaju manje od 50 kg:
Levetiracetam Actavis 750 mg tablets contain Sunset Yellow (E110) 
Levetiracetam Actavis 750 mg tablete sadrže sunset yellow (E110)
Levetiracetam Actavis 250 mg, 500 mg and 1,000 mg film-coated tablets Blisters: 20, 30, 50, 60, 100, 120 and 200 film-coated tablets. 
Levetiracetam Actavis 250 mg, 500 mg i 1000 mg filmom obložene tablete Blisteri: 20, 30, 50, 60, 100, 120 i 200 filmom obloženih tableta.
• If you suffer from kidney problems, follow your doctor's instructions. 
• Ako patite od bubrežnih problema, slijedite upute svog liječnika koji će odlučiti treba li prilagoditi Vašu dozu.
Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function 
Prilagođavanje doze kod dojenčadi, djece i adolescenata s manje od 50 kg tjelesne težine s oštećenom bubrežnom funkcijom
Blisters: 20, 30, 50, 60, 100, 120 and 200 film-coated tablets. 
Veličine pakiranja: Blisteri: 20, 30, 50, 60, 100, 120 i 200 filmom obloženih tableta.
With continued long-term treatment, 47.4 % of the patients were free of tonic-clonic seizures for at least 6 months and 31.5 % were free of tonic-clonic seizures for at least 1 year. 
S nastavkom dugotrajnog liječenja 47,4% bolesnika bilo je barem 6 mjeseci i 31,5% barem 1 godinu bez toničko-kloničkih napadaja.
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6 - 17 the MRHD on a mg/m2 basis). 
Neonatalna i juvenilna ispitivanja na štakorima i psima pokazala su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
• partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age; 
parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od prvog mjeseca života;
Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention 
Amnezija, smetnje pamćenja, poremećaji koordinacije/ataksija, parestezije, smetnje u koncentraciji
(1) An oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. 
(1) Za doze ispod 250 mg i za višestruke doze od 250 mg kada se preporuka o doziranju ne postiže uzimanjem više tableta i kod bolesnika koji ne mogu gutati tablete treba koristiti oralnu otopinu.
Add-on therapy for infants aged from 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg 
Dodatna terapija za dojenčad u dobi od 6 do 23 mjeseca, djecu (2 do 11 godina) i adolescente (12 do 17 godina) s manje od 50 kg tjelesne težine
Oral absolute bioavailability is close to Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. 
Vršna koncentracija u plazmi (Cmax) postiže se 1,3 sata nakon uzimanja lijeka.
Contains colouring agent sunset yellow (E110). 
Sadrži bojilo sunset yellow (E 110).
Crospovidon, povidone, silica colloidal anhydrous, magnesium stearate, polyvinyl alcohol-part. hydrolyzed, macrogol 4000, talc, titanium dioxide (E171), colourants*. 
Drugi sastojci su: krospovidon, povidon, bezvodni koloidni silicijev dioksid, magnezijev stearat, djelomično hidrolizirani polivinilni alkohol, makrogol 4000, talk, titanijev dioksid (E171), bojila*.
• symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function; 
• simptome kao što je smanjen volumen mokraće, umor, mučninu, povraćanje, smetenost i oticanje u nogama, gležnjevima ili stopalima jer to može biti znak naglog smanjenja bubrežne funkcije • kožni osip koji može tvoriti mjehure i izgledati poput malih meta (središnje tamne mrlje okružene svijetlim područjem, s tamnim prstenom oko ruba) (multiformni eritem)
How to take Levetiracetam Actavis 
Kako uzimati Levetiracetam Actavis
Levetiracetam Actavis 750 mg film-coated tablets Blisters: 20, 30, 50, 60, 100, 120 and 200 film-coated tablets. 
Levetiracetam Actavis 750 mg filmom obložene tablete Blisteri: 20, 30, 50, 60, 100, 120 i 200 filmom obloženih tableta.
20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 60 film-coated tablets 100 film-coated tablets 120 film-coated tablets 200 film-coated tablets 60 x 1 film-coated tablets 
20 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 60 filmom obloženih tableta 100 filmom obloženih tableta 120 filmom obloženih tableta 200 filmom obloženih tableta 60 x 1 filmom obloženih tableta
With continued longterm treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizurefree for at least 1 year. 
S nastavkom dugotrajnog liječenja 11,4% bolesnika bilo je barem 6 mjeseci, a 7,2% barem 1 godinu bez napadaja.
An oral solution is the preferred formulation for use in this population. 
Najprikladniji farmaceutski oblik za primjenu u toj populaciji je oralna otopina.
In both population pharmacokinetic analyses, there was about a 20 % increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product. 
U obje farmakokinetičke analize populacije prividni klirens levetiracetama se povećao za oko 20%
The NOAEL was <200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m2 basis). 
NOAEL je za gravidne ženke iznosila <200 mg/kg/dan, a za fetuse 200 mg/kg/dan (što je jednako MRHD-u, engl.
Quincke's oedema [swelling of the face, lips, tongue and throat]); 
Quinckeov edem [oticanje lica, usana, jezika i grla]); • snižena koncentracija natrija u krvi;
Reykjavikurvegur 76-78, 220 Hafnarfjordur, Iceland 
Reykjavikurvegur 76-78, 220 Hafnarfjordur, Island
30 film-coated tablets 100 film-coated tablets 200 film-coated tablets 
30 filmom obloženih tableta 100 filmom obloženih tableta 200 filmom obloženih tableta
Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. 
Dodatna terapija djelomičnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od 1. mjeseca života nadalje koji pate od epilepsije.
Levetiracetam Actavis is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. 
Levetiracetam Actavis je indiciran kao monoterapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih i adolescenata od 16. godine života s novodijagnosticiranom epilepsijom.
750 mg tablet: Indigo carmine (E132), sunset yellow (E110), iron oxide red (E172). 
500 mg tableta: žuti željezov oksid (E172), indigo carmine (E132). 750 mg tableta: indigo carmine (E132), sunset yellow (E110), crveni željezov oksid (E 172).
With continued long-term treatment, 8.6 % of the patients were seizurefree for at least 6 months and 7.8 % were seizure-free for at least 1 year. 
Dugoročno je liječenje pokazalo da 8,6% bolesnika nije imalo napadaje tijekom najmanje 6 mjeseci, a njih 7,8% nije imalo napadaje tijekom najmanje 1 godine.
An oral solution is the formulation to use in infants. 
Oralna otopina je oblik za primjenu kod dojenčadi.
Weight decreased, weight increase 
povećanje tjelesne težine
20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 60 film-coated tablets 100 film-coated tablets 120 film-coated tablets 200 film-coated tablets 
20 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 60 filmom obloženih tableta 100 filmom obloženih tableta 120 filmom obloženih tableta 200 filmom obloženih tableta
• convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), 
• konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), bezvoljnost (gubitak energije i entuzijazma), tremor (nevoljno drhtanje);
(5) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended. 
. (5) Nakon dijalize preporučuje se dodatna doza od 5 do 10 mg/kg (0,05 do 0,10 ml/kg)
In the elderly, the half-life is increased by about 40 % (10 to 11 hours). 
U starijih osoba poluvijek u plazmi povećano je za oko 40% (10 do 11 sati), što je u svezi sa smanjenjem bubrežne funkcije unutar te populacije (vidjeti dio 4.2).
One tablet of Levetiracetam Actavis 1,000 mg contains 1,000 mg of levetiracetam. 
Jedna tableta Levetiracetama Actavis 1000 mg sadrži 1000 mg levetiracetama.